Literature DB >> 25190513

A discrete-time survival model with random effects for designing and analyzing repeated low-dose challenge experiments.

Chaeryon Kang1, Ying Huang2, Christopher J Miller3.   

Abstract

Repeated low-dose (RLD) challenge designs are important in HIV vaccine research. Current methods for RLD designs rely heavily on an assumption of homogeneous risk of infection among animals, which, upon violation, can lead to invalid inferences and underpowered study designs. We propose to fit a discrete-time survival model with random effects that allows for heterogeneity in the risk of infection among animals and allows for predetermined challenge dose changes over time. Based on this model, we derive likelihood ratio tests and estimators for vaccine efficacy. A two-stage approach is proposed for optimizing the RLD design under cost constraints. Simulation studies demonstrate good finite sample properties of the proposed method and its superior performance compared to existing methods. We illustrate the application of the heterogeneous infection risk model on data from a real simian immunodeficiency virus vaccine study using Rhesus Macaques. The results of our study provide useful guidance for future RLD experimental design.
© The Author 2014. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Discrete-time survival model with random effects; HIV vaccine prevention research; Heterogeneous infection risk; Repeated low-dose challenge experiment; Sample size calculation

Mesh:

Year:  2014        PMID: 25190513      PMCID: PMC4786638          DOI: 10.1093/biostatistics/kxu040

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  13 in total

1.  Statistical tests of gamma-distributed rate heterogeneity in models of sequence evolution in phylogenetics.

Authors:  N Goldman; S Whelan
Journal:  Mol Biol Evol       Date:  2000-06       Impact factor: 16.240

2.  HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.

Authors:  Dennis Ellenberger; Ronald A Otten; Bin Li; Michael Aidoo; I Vanessa Rodriguez; Carlos A Sariol; Melween Martinez; Michael Monsour; Linda Wyatt; Michael G Hudgens; Edmundo Kraiselburd; Bernard Moss; Harriet Robinson; Thomas Folks; Salvatore Butera
Journal:  Virology       Date:  2006-05-24       Impact factor: 3.616

3.  A discrete survival model with random effects: an application to time to pregnancy.

Authors:  T H Scheike; T K Jensen
Journal:  Biometrics       Date:  1997-03       Impact factor: 2.571

4.  Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge.

Authors:  Matthew R Reynolds; Andrea M Weiler; Shari M Piaskowski; Holly L Kolar; Ann J Hessell; Madelyn Weiker; Kim L Weisgrau; Enrique J León; W Eric Rogers; Robert Makowsky; Adrian B McDermott; Rosanne Boyle; Nancy A Wilson; David B Allison; Dennis R Burton; Wayne C Koff; David I Watkins
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

5.  Adding Subjects or Adding Measurements in Repeated Measurement Studies Under Financial Constraints.

Authors:  Song Zhang; Chul Ahn
Journal:  Stat Biopharm Res       Date:  2011-02-01       Impact factor: 1.452

6.  Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.

Authors:  Huma Qureshi; Zhong-Min Ma; Ying Huang; Gregory Hodge; Michael A Thomas; Janet DiPasquale; Veronique DeSilva; Linda Fritts; Andrew J Bett; Danilo R Casimiro; John W Shiver; Marjorie Robert-Guroff; Michael N Robertson; Michael B McChesney; Peter B Gilbert; Christopher J Miller
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

7.  Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

Authors:  Merlin L Robb; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Prayura Kunasol; Chirasak Khamboonruang; Prasert Thongcharoen; Patricia Morgan; Michael Benenson; Robert M Paris; Joseph Chiu; Elizabeth Adams; Donald Francis; Sanjay Gurunathan; Jim Tartaglia; Peter Gilbert; Don Stablein; Nelson L Michael; Jerome H Kim
Journal:  Lancet Infect Dis       Date:  2012-05-30       Impact factor: 25.071

8.  Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments.

Authors:  Michael G Hudgens; Peter B Gilbert; John R Mascola; Chih-Da Wu; Dan H Barouch; Steven G Self
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

9.  Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.

Authors:  Roland R Regoes; Ira M Longini; Mark B Feinberg; Silvija I Staprans
Journal:  PLoS Med       Date:  2005-07-19       Impact factor: 11.069

10.  The role of exposure history on HIV acquisition: insights from repeated low-dose challenge studies.

Authors:  Roland R Regoes
Journal:  PLoS Comput Biol       Date:  2012-11-08       Impact factor: 4.475

View more
  2 in total

1.  A method to address between-subject heterogeneity for identification of principal surrogate markers in repeated low-dose challenge HIV vaccine studies.

Authors:  Andrew J Spieker; Ying Huang
Journal:  Stat Med       Date:  2017-07-31       Impact factor: 2.373

2.  The role of specialized hospital units in infection and mortality risk reduction among patients with hematological cancers.

Authors:  Raïsa Carmen; Galit B Yom-Tov; Inneke Van Nieuwenhuyse; Bram Foubert; Yishai Ofran
Journal:  PLoS One       Date:  2019-03-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.